龍芯中科(688047.SH):目前公司整體人員配置滿足相關部門崗位需求
格隆匯2月1日丨龍芯中科(688047.SH)投資者關係活動記錄表顯示,2019年底、2020年底、2021年底,員工人數分別為400多人、600多人、800多人。2022年底,公司員工為913人,其中研發技術人員數量佔比67.47%。在過去幾年,龍芯人員已經經過了一輪擴張,需要穩一穩。2022年公司開始執行穩員增效的方針,招聘增速放緩,更加關注於提升員工個體能效。目前,公司整體人員配置滿足相關部門崗位需求,後續員工數量方面上將總體保持穩健態勢。龍芯人員數量的增長要和公司發展規模相匹配,公司更多考慮的是人均銷售收入的變化,避免盲目擴張。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.